Marinus Finds Silver Lining In Ganaxolone Trial Miss
Executive Summary
The biotech announces another poor performance for its lead drug candidate, but puts a positive spin on the data and plans continued development.
You may also be interested in...
Marinus Charts The Way Forward For Ganaxolone Amid Business Challenges
Phase II results for Marinus’s ganaxolone in postpartum depression are a mixed bag, but the US biotech sees potential in this and other neurological indications, probably with partners.
Marinus Nixes Ganaxolone Indication After Trial Fail
The biotech vows to continue development of the drug in pediatric indications after a late-stage failure in an adult seizure disorder.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.